Callan JMB Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wayne Williams
- Full Time Employees
- 26
- Sector
- Industrials
- Industry
- Integrated Freight & Logistics
- Address
- 244 Flightline Drive Spring Branch TX United States of America 78070-6241
- IPO Date
- Feb 6, 2025
- CIK
- 0002032545
- Website
- callanjmb.com
- Similar Companies
- Business
- Callan JMB Inc. (NASDAQ: CJMB) provides vertically integrated thermal management logistics and fulfillment services to the life sciences, healthcare, pharmaceuticals, diagnostics, food, and emergency management industries through its subsidiary Coldchain Technology Services, LLC; core offerings include proprietary reusable VIP thermal shippers in 9-inch, 12-inch, and 24-inch sizes maintaining temperatures from -40°C to +70°C without dry ice or gel packs, end-to-end fulfillment with cGMP-compliant storage and distribution, Sentry real-time GPS and temperature monitoring platform upgraded to Sentry 4 for mobile tracking in October 2025, Ship2Q ultraviolet disinfection and recertification process for shipper reuse, emergency preparedness and response solutions for vaccines and medical stockpiles, specialty packaging for perishable non-pharma goods, and technical services for quality assurance and regulatory compliance. The company serves government agencies including the City of Chicago, Oregon Health Authority, Texas Department of State Health Services, and private clients such as BioBridge Global, with operations centered in the United States and expanding internationally via Callan JMB Services (India) Private Limited established in July 2025 for temperature-controlled pharmaceutical storage and distribution in Pune, Maharashtra. Founded in 2006 and headquartered at 244 Flightline Drive in Spring Branch, Texas, Callan JMB completed a $5.12 million initial public offering on February 6, 2025. Recent developments include a joint venture with Revival Health announced May 21, 2025 to bolster supply chains for health and wellness products; appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs on April 25, 2025; extension of its Chicago contract through June 2026 with $1.5 million additional funding in July 2025 bringing total value to $9.1 million; expansion into food sampling reclamation operations and a preliminary agreement in November 2025 to install oral drug delivery manufacturing equipment at its Texas facility; support for measles outbreak responses in Texas, New Mexico, and Chicago; and a second five-year contract with Oregon Health Authority awarded February 11, 2025.
Callan JMB and Alabama State University Announce Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience
Callan JMB and Alabama State University Announce Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience
Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex
Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex
Callan JMB Expands Oregon Public Health Support Capabilities Through State VFC Authorization
Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement
Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC
Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC
Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer
Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement
Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID
Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript
Callan JMB Announces Participation in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026
Head to Head Comparison: C.H. Robinson Worldwide (NASDAQ:CHRW) versus Callan JMB (NASDAQ:CJMB)
Financial Review: Callan JMB (NASDAQ:CJMB) versus Lakeside (NASDAQ:LSH)
Callan JMB (NASDAQ:CJMB) versus Jayud Global Logistics (NASDAQ:JYD) Financial Analysis
Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility
Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update
Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy